A patient slides a small brown bottle across the desk. She found it at the pharmacy, near the melatonin and the fish oil, and she wants to know if it actually does anything or if she just spent fourteen dollars on scented capsules. The label says lavender. You have about four seconds to decide whether you sound informed or dismissive.
If that scenario makes you reach for a vague “there’s not much evidence on supplements,” it is worth slowing down. The supplement in question is almost certainly Silexan, a standardized lavender oil preparation, and the evidence behind it is better than most clinicians realize. Carlat Publishing made exactly this point in a recent piece bluntly titled “The Anxiety Treatment Most U.S. Clinicians Haven’t Heard Of.” For a profession that prides itself on staying current, that headline should sting a little.
What Silexan actually is
Silexan is not a tincture or an essential oil you diffuse. It is an oral preparation of lavender oil produced by steam distillation from Lavandula angustifolia flowers, standardized to specific concentrations of its two active constituents, linalool and linalyl acetate. The standardization matters. It is the difference between a defined product that has been studied in randomized trials and the generic “lavender” sitting in a hundred different bottles with a hundred different compositions.
Here is the part that trips people up. In much of Europe, Silexan is a licensed medicine. In Germany it is sold as Lasea and prescribed for anxiety. In the United States, the same preparation is marketed over the counter as a dietary supplement, most commonly under the name CalmAid. So your patient bought, without a prescription and without insurance, a product that a psychiatrist in Munich would write a script for. That regulatory split shapes everything about how this fits into a private practice, and we will come back to it.
The evidence is the surprising part
The trial people point to most often was published in 2014 in the International Journal of Neuropsychopharmacology, led by Siegfried Kasper. It enrolled 539 adults who met DSM-5 criteria for generalized anxiety disorder, all with a Hamilton Anxiety Scale score of at least 18, meaning genuinely symptomatic patients rather than the worried well. They were randomized, double-blind, to Silexan 160 mg daily, Silexan 80 mg daily, paroxetine 20 mg daily, or placebo, for ten weeks.

The HAMA scores dropped by 14.1 points on Silexan 160 mg, 12.8 points on Silexan 80 mg, 11.3 points on paroxetine, and 9.5 points on placebo. Both Silexan doses separated from placebo at a conventional significance threshold. Paroxetine, the established SSRI in the study, only showed a trend toward significance in the full analysis set. Read that again. In a head-to-head trial, the lavender extract beat placebo cleanly and the SSRI did not.
That comparison should be read carefully rather than triumphantly. A single trial where the active comparator underperforms its own track record is a reason for interest, not a reason to abandon SSRIs, which carry decades of evidence Silexan does not have. What the trial does establish is that Silexan is a real anxiolytic rather than an expensive placebo, and that it earned its result against a fair comparator rather than against an empty arm.
Carlat’s reviewers, who are not in the habit of overselling anything, have gone as far as citing an effect size in the range of 0.9 for Silexan, against roughly 0.3 for antidepressants and 0.5 for benzodiazepines in anxiety. Effect sizes are slippery across trials and you should hold that number loosely, but even a fraction of that advantage would be clinically meaningful. This is not one stray positive study either. A 2019 network meta-analysis in Scientific Reports pooled the anxiety trials, and a 2024 paper in the International Journal of Psychiatry in Clinical Practice reported on real-world long-term use. The signal has held up.
The tolerability data deserve equal attention. In the Kasper trial, adverse event rates for Silexan were comparable to placebo and lower than for paroxetine. The most reliably reported side effect is eructation, the faint lavender burp, which patients find more amusing than distressing. There is no sexual dysfunction, no activation, no discontinuation syndrome to plan around.
Why it does not behave like a benzodiazepine
The mechanism explains a lot, and it is worth being able to describe it without hand-waving. Silexan does not act on GABA-A receptors. That single fact separates it from benzodiazepines and from the worry that defines them. Its primary action appears to be inhibition of voltage-gated calcium channels at presynaptic nerve terminals. Linalool and linalyl acetate reduce calcium influx during depolarization, which means less neurotransmitter release across the limbic circuits involved in anxiety. There is also evidence of partial agonism at the 5-HT1A receptor, the same target buspirone works through.

The practical consequence is that the conditions for tolerance and physical dependence do not appear to develop under normal dosing. Voltage-gated calcium channels do not downregulate the way GABA-A receptors do under chronic benzodiazepine exposure. For any PMHNP who has inherited a patient on a standing benzodiazepine prescription and spent months trying to taper it, an anxiolytic option with a clean tolerance profile is not a footnote. It is a tool.
One practical detail belongs right here. Silexan is not fast. Like an SSRI, and unlike a benzodiazepine, it works gradually, with separation from placebo typically emerging over the first two to four weeks and continuing to build toward the ten-week mark. Patients need to hear that up front. Someone expecting same-day relief will quit by day three and conclude it does nothing. Set the expectation that this is a daily preventive agent, not a rescue one, and you will get a fairer trial of it.
What this means for your private practice
The supplement status is a double-edged thing, and pretending otherwise does your patients no favors. On the helpful side, there is no formulary, no prior authorization, no step therapy. A patient can act on your recommendation the same afternoon. For cash-pay practices and integrative-leaning practices, where patients arrive specifically asking what they can do besides “another pill from insurance,” that accessibility is real. You become the clinician who can actually answer the lavender question instead of waving it off.
It also reframes a conversation that usually goes badly. When a patient raises a supplement and the clinician shuts it down, the patient often does not stop taking it. They just stop mentioning it. An informed, specific answer keeps that disclosure flowing, and that flow is the only reliable way you find out what your patient is actually putting in their body.
The other edge is quality control. Because CalmAid is regulated as a supplement and not a drug, it does not carry the manufacturing oversight a prescription medication does. The trials were run on the specific standardized Silexan preparation, not on whatever else is labeled lavender. If you are going to recommend it, recommend the studied product by name and the studied dose, generally 80 mg once daily, and tell the patient why the specific product matters. Vague advice to “try lavender” is how the evidence base gets diluted into nothing.

There is also a positioning angle here that is easy to miss. Patients are already searching for natural anxiety options, and most of what they find online is junk. A practice that can speak about Silexan with actual citations, that can explain the Kasper trial and the mechanism and the limits, signals a particular kind of competence. It says you take integrative requests seriously enough to evaluate them properly rather than reflexively. That reputation travels. In a market where patients increasingly choose their PMHNP the way they choose any other professional, being genuinely current on the questions they are actually asking is a quiet differentiator.
Where it fits, and where it does not
None of this makes Silexan a replacement for a careful assessment. The trial population was generalized anxiety disorder, not panic disorder, not PTSD, not the anxious presentation of an undiagnosed bipolar disorder. It does not treat suicidality, it does not address severe functional impairment that needs a faster and more aggressive approach, and it is not a reason to skip the diagnostic work. It is most reasonable to think of it as an option for mild to moderate GAD, for the patient who wants to try something before an SSRI, for the patient who could not tolerate an SSRI, or as part of a benzodiazepine-sparing strategy.
Document it the way you would document any clinical recommendation. Note that you discussed a standardized lavender oil preparation with supporting randomized trial evidence, that you reviewed it as a supplement rather than an FDA-approved drug, that you covered expected effects and the realistic timeline, and that the patient understood all of that. The conversation is not complicated. It just needs to happen on the record.
It also helps to ask what else the patient is taking. Silexan has a benign interaction profile, but a patient stacking it with an SSRI, a sedating antihistamine, and an over-the-counter sleep aid is worth a closer look, if only so you understand the full picture of what is shaping their symptoms and their sleep.
The larger point is the one Carlat was making. There is a real anxiolytic, with real trial data and a clean safety profile, sitting on a shelf your patients walk past every week, and a lot of clinicians cannot say a single informed sentence about it. Closing that gap costs you an afternoon of reading. The return is a better answer the next time a brown bottle slides across your desk.
If you want more practical, evidence-grounded breakdowns like this one, written for PMHNPs who are building and running their own practices, visit pmhnpwebsite.com and make it part of your regular reading.
